positive prelim data from a Phase 1 study-leukemia treatment

Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Key findings include:

- Marrow blast reductions observed in all evaluable patients (6 patients).

- 6 of 7 patients enrolled remain on study.

- Patients enrolled experienced a median of 3 prior lines of treatment (range 1-4).

- Two patients experienced a marrow complete response, one with blast count going from 23% pretreatment to 1% on treatment, and the other going from 11% pretreatment to 2% on treatment.

- No DLTs observed in 7 DLT-evaluable patients in the 200 mg BID and 300 mg BID cohorts.

- Enrollment has begun in the 400 mg BID cohort.

Curis said its CA-4948 monotherapy in adult patients was well tolerated, has demonstrated signs of biologic activity in the ongoing study and is capable of achieving "relevant levels of drug exposure."

finance.yahoo.com/news/curis-announces-positive-preliminary-data-120000313.html